

Welcome to our resource hub for ESC 2025! This is a one-stop-shop for all your ESC needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Previous ESC Coverage on CCKB](#)

Useful Conference Links

1. [Day-by-Day Conference Preview](#)

Day-of Conference Reports

1. [ESC 2025 Day #1 Highlights](#)
2. [ESC 2025 Day #2 Highlights](#)
3. [ESC 2025 Day #3 Highlights](#)
4. [ESC 2025 Day #4 Highlights](#)

Diabetes Therapy Highlights

1. [Inaugural session welcomes attendees to the 75th ESC Congress](#) with a theme on global health
 2. [Post-hoc analysis of the SOUL trial](#) shows benefit of Rybelsus (oral semaglutide) in heart failure outcomes
 3. [Post-hoc analysis of the SELECT trial](#): Dr. Plutzky finds semaglutide reduces MACE, atrial fibrillation, and HF risk
 4. [Post-hoc analysis of CREDENCE trial](#) shows benefit of continued canagliflozin use in people with T2D, CKD, and eGFR <20 mL/min/1.73 m²
 5. [Drs. Andreea Ciudin and Barbara McGowan push for new diagnostic framework](#) of obesity and review treatment landscape
 6. [Liraglutide is associated with improved outcomes](#) for patients with HFpEF and obesity
 7. [Combination therapy with SGLT-2 inhibitors and GLP-1 RAs](#) reduce all-cause mortality in patients with T2D
 8. [Multinational Emp-Activity study](#) shows that empagliflozin improves quality of life and cardiac function in real-world patients with heart failure
 9. [Impact of GLP-1 RAs on muscle loss](#): Lively debate discussing this effect is in cardiometabolic disease management
 10. [Findings from FINEARTS-HF](#): Finerenone demonstrates efficacy for severe heart failure
 11. [Post-hoc analysis of SURMOUNT-1](#): Over a quarter of tirzepatide group meets clinical cardiometabolic targets
-

12. [Post-hoc analysis of the SOUL trial](#) shows benefits of Rybelsus (oral semaglutide) for improving cardiovascular markers
13. [Pooled analysis of the SCORED and SOLOIST-WHF trials](#) show consistent CV benefits of sotagliflozin in older adults
14. [Prof. Naveed Sattar calls for the targeting of prediabetes](#) to reduce cardiovascular risk
15. [Do triglycerides matter?](#) Decoding a key risk factor for ASCVD
16. [Cardiovascular outcomes in a SELECT-like obesity population](#): Real-world insights from the Swedish AROS study
17. [Save lives, hearts, and kidneys](#): Dr. Katherine Tuttle provides an overview of CKD management in diabetes
18. [Evidence-based strategies to address the “conundrum” of HFpEF](#): SGLT-2 inhibitors, MRAs, inflammation targets, and incretin therapies
19. [Factors associated with difficult-to-manage hypertension in T2D](#)
20. [Increasing trends of cardiovascular mortality rates](#) related to hypertension and diabetes in the US
21. [Dapagliflozin is safe for use in patients hospitalized](#) for acute heart failure
22. [Real-world STEER study](#) finds semaglutide is superior to tirzepatide for CV risk reduction
23. [Post-hoc analysis of the SURMOUNT-5 trial](#): Tirzepatide may have superior projected 10-year CV risk reduction compared to semaglutide
24. [Post-hoc analysis of the CONFIDENCE trial](#): Simultaneous initiation of finerenone and empagliflozin rapidly reduces albuminuria across KDIGO risk categories
25. [Population-based study spanning two decades](#) shows associations of serum insulin levels with cardiovascular disease incidence and mortality
26. [Comparing glucose-lowering agents for atherosclerotic plaque prevention](#) using coronary CT angiography
27. [Post-hoc analysis of the STRIDE trial](#) finds consistent benefits of semaglutide on PAD regardless of sex
28. [Diabetes and prediabetes as risk factors for heart failure](#): Population-based cohort study highlight potential for preventative efforts
29. [Targeting A1c goals for renal function](#) in patients with chronic coronary syndrome
30. [SGLT-2 inhibitors demonstrate heterogeneous effects](#) in people with diabetes and without established cardiovascular disease
31. [Damaged hearts require more sleep](#): Mechanistic answers to why sleep improves cardiovascular health
32. [KOL Commentary on cardiovascular benefits of semaglutide and tirzepatide](#)
33. [GLP-1 RAs and SGLT-2 inhibitors are underutilized](#) in primary care for patients with diabetes and CAD
34. [Glucose lowering therapies should be prescribed before and after MI](#) among patients with T2D
35. [A large-scale study quantifies the impact of age of onset and duration of T2D](#) on life expectancy and serious health outcomes
36. [Systematic review and meta-analysis reinforce the efficacy and safety of GLP-1 RAs](#) in obesity-related HFpEF
37. [Cardiovascular-kidney-metabolic syndrome is prevalent in healthy populations](#) and linked to mortality
38. [Transitioning from overweight childhood status to normal BMI](#) in adulthood mitigates cardiovascular-kidney-metabolic risks
39. [Prediabetes increases cardiovascular disease risk by a \(very\) statistically significant 21%](#), a major change upwards
40. [His Majesty King Felipe VI encourages continued focus on addressing cardiovascular disease](#), promoting prevention and raising awareness
41. [Cardiology beyond borders](#): What this means in practice

42. [Broad global health challenges continue](#)

Previous ESC Coverage on CCKB

1. [ESC 2024 Resource Hub](#)
2. [ESC 2023 Resource Hub](#)
3. [ESC 2022 Resource Hub](#)
4. [ESC 2021 Resource Hub](#)
5. [ESC 2020 Full Report](#)
6. [ESC 2019 Full Report](#)
7. [ESC 2018 Full Report](#)
8. [ESC 2017 Full Report](#)